Biogen

Biogen Q4 Earnings Beat Estimates, FY26 Guidance Exceeds Expectations

Biogen shares surge 8.19% after hours on Q4 earnings beat driven by Leqembi, Skyclarys, and Zurzuvae growth.

Biogen's 2026 EPS Guidance: $15.25-$16.25, Advancing Growth Products and Pipeline

Biogen shares rise 5.37% intraday after Q4 earnings beat driven by Alzheimer's drug sales and growth products.

Biogen Q4 Earnings Beat Expectations, 2026 Profit Outlook Strong

Catalyst<ul> <li>Recent Bullish Engulfing and WR Oversold signals in late November and early December point to rebound momentum for BIIB.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a weak state, and we need to pay attention to the risk of decline.</li> <li>Bearish signals are obviously dominant (4 bearish vs 0 bullish).</li> <li>Net outflows across all fund flow buckets indicate widespread disinterest or pessimism from institutional and retail investors.</li> <li>Market expectations tend to be pessimistic, with analyst ratings showing differences in opinion.</li></ul>

Key Factors

Biogen reported Q4 2025 adjusted EPS of $1.99, exceeding analyst estimates by 22.1%, driven by strong performance in growth products including Leqembi, Skyclarys, and Zurzuvae. The company provided 2026 EPS guidance of $15.25–$16.25, above the $14.92 consensus, reflecting improved financial discipline and resilience in key therapeutic areas despite MS revenue declines. Biogen’s Q4 revenue reached $2.28 billion, up 3.6% from estimates, with Leqembi achieving $134 million in global in-market sales, a 54% YoY increase.

BIIB News